Anti-Hypertensive Activity of Some Selected Unani Formulations: An Evidence-Based Approach for Verification of Traditional Unani Claims Using LC-MS/MS for the Evaluation of Clinically Relevant Blood Parameters in Laboratory Rats

Background: Systemic arterial hypertension, which is associated with an increased risk of cardiovascular disease(CVD), is the most significant modifiable risk factor for mortality and morbidity worldwide. WHO has recognized Unanipathy as an alternate system of medicine. The aim of the present study...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical medicine 2022-08, Vol.11 (15), p.4628
Hauptverfasser: Shaharyar, Md Adil, Bhowmik, Rudranil, Afzal, Obaid, Altamimi, Abdulmalik S A, Alzarea, Sami I, Almalki, Waleed Hassan, Ali, Sk Zeeshan, Mandal, Pallab, Mandal, Avishek, Ayoob, Mohd, Kazmi, Imran, Karmakar, Sanmoy
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 15
container_start_page 4628
container_title Journal of clinical medicine
container_volume 11
creator Shaharyar, Md Adil
Bhowmik, Rudranil
Afzal, Obaid
Altamimi, Abdulmalik S A
Alzarea, Sami I
Almalki, Waleed Hassan
Ali, Sk Zeeshan
Mandal, Pallab
Mandal, Avishek
Ayoob, Mohd
Kazmi, Imran
Karmakar, Sanmoy
description Background: Systemic arterial hypertension, which is associated with an increased risk of cardiovascular disease(CVD), is the most significant modifiable risk factor for mortality and morbidity worldwide. WHO has recognized Unanipathy as an alternate system of medicine. The aim of the present study is to investigate the anti-hypertensive activity of some selected unani formulations using L-NAME model. Method: Group I or hypertensive control group: L-NAME administered for 7 days and left for the next 7 days; Group II or KASgroup: L-NAME administered (i.p) for 7 days and L-NAME + KAS (1000 mg/kg b.w) for the next 7 days; Group III or DMM group: L-NAME administered (i.p) for 7 days and L-NAME + DMM (2000 mg/kg b.w) for the next 7 days; Group IV or MSR group: L-NAME administered (i.p) for 7 days and L-NAME + MSR (300 mg/kg b.w) for the next 7 days; Group V or HJ group: L-NAME administered (i.p) for 7 days and L-NAME + HJ (113 mg/kg b.w) for the next 7 days; Group VI or KGS group: L-NAME administered (i.p) for 7 days and L-NAME +KGS (2000 mg/kg b.w) for the next 7 days. Non-invasive systolic blood pressure and RR-interval (ECG) was measured. Plasma was investigated forsodium, potassium, nitrite, ANP, adrenaline, noradrenaline and aldosterone on day 0, 7 and 14 using LC-MS/MS. Result: Treatment showed a non-significant lowreduction in SBP (systolic blood pressure) of KAS, MSR and HJ while that of DMM was quite significant (p < 0.05), but in the case of KGS, SBP increased. DMM on day 14 significantly (p < 0.05) reduced plasma nitrite while no significant plasma Na+ was noted. In the case of both DMM and KGS, potassium increased significantly (p < 0.05) on day 14. No significant changes in plasma ANP and aldosterone was observed against DMM and KGS while blood levels of adrenaline and noradrenaline significantly (p < 0.05) changed. No significant change in body weight was found. Conclusions: L-NAME KAS, MSR and HJ showed no change in SBP while DMM showed a significant reduction in SBP with decreased plasma nitrite. Probably, DMM may have anti-hypertensive activity mediated through NO inhibition while KGS may involve central sympathomimetic action.
doi_str_mv 10.3390/jcm11154628
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9369749</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2700649111</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-f6054b21a90f1c355a77d3459b3d362b06d1bf128bfe0cfeee8ec63c169f62eb3</originalsourceid><addsrcrecordid>eNpdkl1rFDEUhgdRbKm98l4C3ggyNh_z6YWwXVorbFHcrrdDJnPSzZJJpklmYP-vP8Tsdl1Wc5OEPOfhJbxJ8pbgT4zV-GojekJInhW0epGcU1yWKWYVe3lyPksuvd_guKoqo6R8nZyxvM4LmuXnye-ZCSq92w7gAhivJkAzEdSkwhZZiZa2B7QEDSJAh1aGG4VuretHzYOyxn9GM4NuJtWBEZBecx-p2TA4y8UaSevQL3BKKrGnd8IHxzu1u3B90M01V71HK6_MI1rM0_vl1f1yPxvWEN1cj8fpuVYmyrTeop8x1MRNQNfa2g794I73EMB5pAxa8NY6HqyLHA_-TfJKcu3h8rBfJKvbm4f5Xbr4_vXbfLZIRYbrkMoC51lLCa-xJILlOS_LjmV53bKOFbTFRUdaSWjVSsBCAkAFomCCFLUsKLTsIvny7B3GtodOgAmO62Zwqudu21iumn9fjFo3j3ZqalbUZVZHwYeDwNmnEXxoeuUFaM0N2NE3tMSUVIxmNKLv_0M3dnTxW_cULrI69iJSH58p4az3DuQxDMHNrkDNSYEi_e40_5H9Wxf2B-jVxZA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2700649111</pqid></control><display><type>article</type><title>Anti-Hypertensive Activity of Some Selected Unani Formulations: An Evidence-Based Approach for Verification of Traditional Unani Claims Using LC-MS/MS for the Evaluation of Clinically Relevant Blood Parameters in Laboratory Rats</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Shaharyar, Md Adil ; Bhowmik, Rudranil ; Afzal, Obaid ; Altamimi, Abdulmalik S A ; Alzarea, Sami I ; Almalki, Waleed Hassan ; Ali, Sk Zeeshan ; Mandal, Pallab ; Mandal, Avishek ; Ayoob, Mohd ; Kazmi, Imran ; Karmakar, Sanmoy</creator><creatorcontrib>Shaharyar, Md Adil ; Bhowmik, Rudranil ; Afzal, Obaid ; Altamimi, Abdulmalik S A ; Alzarea, Sami I ; Almalki, Waleed Hassan ; Ali, Sk Zeeshan ; Mandal, Pallab ; Mandal, Avishek ; Ayoob, Mohd ; Kazmi, Imran ; Karmakar, Sanmoy</creatorcontrib><description>Background: Systemic arterial hypertension, which is associated with an increased risk of cardiovascular disease(CVD), is the most significant modifiable risk factor for mortality and morbidity worldwide. WHO has recognized Unanipathy as an alternate system of medicine. The aim of the present study is to investigate the anti-hypertensive activity of some selected unani formulations using L-NAME model. Method: Group I or hypertensive control group: L-NAME administered for 7 days and left for the next 7 days; Group II or KASgroup: L-NAME administered (i.p) for 7 days and L-NAME + KAS (1000 mg/kg b.w) for the next 7 days; Group III or DMM group: L-NAME administered (i.p) for 7 days and L-NAME + DMM (2000 mg/kg b.w) for the next 7 days; Group IV or MSR group: L-NAME administered (i.p) for 7 days and L-NAME + MSR (300 mg/kg b.w) for the next 7 days; Group V or HJ group: L-NAME administered (i.p) for 7 days and L-NAME + HJ (113 mg/kg b.w) for the next 7 days; Group VI or KGS group: L-NAME administered (i.p) for 7 days and L-NAME +KGS (2000 mg/kg b.w) for the next 7 days. Non-invasive systolic blood pressure and RR-interval (ECG) was measured. Plasma was investigated forsodium, potassium, nitrite, ANP, adrenaline, noradrenaline and aldosterone on day 0, 7 and 14 using LC-MS/MS. Result: Treatment showed a non-significant lowreduction in SBP (systolic blood pressure) of KAS, MSR and HJ while that of DMM was quite significant (p &lt; 0.05), but in the case of KGS, SBP increased. DMM on day 14 significantly (p &lt; 0.05) reduced plasma nitrite while no significant plasma Na+ was noted. In the case of both DMM and KGS, potassium increased significantly (p &lt; 0.05) on day 14. No significant changes in plasma ANP and aldosterone was observed against DMM and KGS while blood levels of adrenaline and noradrenaline significantly (p &lt; 0.05) changed. No significant change in body weight was found. Conclusions: L-NAME KAS, MSR and HJ showed no change in SBP while DMM showed a significant reduction in SBP with decreased plasma nitrite. Probably, DMM may have anti-hypertensive activity mediated through NO inhibition while KGS may involve central sympathomimetic action.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm11154628</identifier><identifier>PMID: 35956245</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Animals ; Antihypertensives ; Blood pressure ; Clinical medicine ; Electrocardiography ; Hypertension ; Laboratories ; Medical practices ; Medical research ; Medicine ; Potassium</subject><ispartof>Journal of clinical medicine, 2022-08, Vol.11 (15), p.4628</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-f6054b21a90f1c355a77d3459b3d362b06d1bf128bfe0cfeee8ec63c169f62eb3</citedby><cites>FETCH-LOGICAL-c409t-f6054b21a90f1c355a77d3459b3d362b06d1bf128bfe0cfeee8ec63c169f62eb3</cites><orcidid>0000-0003-2319-340X ; 0000-0003-1881-5219 ; 0000-0003-4007-4023 ; 0000-0002-4188-5592</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369749/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369749/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35956245$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shaharyar, Md Adil</creatorcontrib><creatorcontrib>Bhowmik, Rudranil</creatorcontrib><creatorcontrib>Afzal, Obaid</creatorcontrib><creatorcontrib>Altamimi, Abdulmalik S A</creatorcontrib><creatorcontrib>Alzarea, Sami I</creatorcontrib><creatorcontrib>Almalki, Waleed Hassan</creatorcontrib><creatorcontrib>Ali, Sk Zeeshan</creatorcontrib><creatorcontrib>Mandal, Pallab</creatorcontrib><creatorcontrib>Mandal, Avishek</creatorcontrib><creatorcontrib>Ayoob, Mohd</creatorcontrib><creatorcontrib>Kazmi, Imran</creatorcontrib><creatorcontrib>Karmakar, Sanmoy</creatorcontrib><title>Anti-Hypertensive Activity of Some Selected Unani Formulations: An Evidence-Based Approach for Verification of Traditional Unani Claims Using LC-MS/MS for the Evaluation of Clinically Relevant Blood Parameters in Laboratory Rats</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>Background: Systemic arterial hypertension, which is associated with an increased risk of cardiovascular disease(CVD), is the most significant modifiable risk factor for mortality and morbidity worldwide. WHO has recognized Unanipathy as an alternate system of medicine. The aim of the present study is to investigate the anti-hypertensive activity of some selected unani formulations using L-NAME model. Method: Group I or hypertensive control group: L-NAME administered for 7 days and left for the next 7 days; Group II or KASgroup: L-NAME administered (i.p) for 7 days and L-NAME + KAS (1000 mg/kg b.w) for the next 7 days; Group III or DMM group: L-NAME administered (i.p) for 7 days and L-NAME + DMM (2000 mg/kg b.w) for the next 7 days; Group IV or MSR group: L-NAME administered (i.p) for 7 days and L-NAME + MSR (300 mg/kg b.w) for the next 7 days; Group V or HJ group: L-NAME administered (i.p) for 7 days and L-NAME + HJ (113 mg/kg b.w) for the next 7 days; Group VI or KGS group: L-NAME administered (i.p) for 7 days and L-NAME +KGS (2000 mg/kg b.w) for the next 7 days. Non-invasive systolic blood pressure and RR-interval (ECG) was measured. Plasma was investigated forsodium, potassium, nitrite, ANP, adrenaline, noradrenaline and aldosterone on day 0, 7 and 14 using LC-MS/MS. Result: Treatment showed a non-significant lowreduction in SBP (systolic blood pressure) of KAS, MSR and HJ while that of DMM was quite significant (p &lt; 0.05), but in the case of KGS, SBP increased. DMM on day 14 significantly (p &lt; 0.05) reduced plasma nitrite while no significant plasma Na+ was noted. In the case of both DMM and KGS, potassium increased significantly (p &lt; 0.05) on day 14. No significant changes in plasma ANP and aldosterone was observed against DMM and KGS while blood levels of adrenaline and noradrenaline significantly (p &lt; 0.05) changed. No significant change in body weight was found. Conclusions: L-NAME KAS, MSR and HJ showed no change in SBP while DMM showed a significant reduction in SBP with decreased plasma nitrite. Probably, DMM may have anti-hypertensive activity mediated through NO inhibition while KGS may involve central sympathomimetic action.</description><subject>Animals</subject><subject>Antihypertensives</subject><subject>Blood pressure</subject><subject>Clinical medicine</subject><subject>Electrocardiography</subject><subject>Hypertension</subject><subject>Laboratories</subject><subject>Medical practices</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Potassium</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkl1rFDEUhgdRbKm98l4C3ggyNh_z6YWwXVorbFHcrrdDJnPSzZJJpklmYP-vP8Tsdl1Wc5OEPOfhJbxJ8pbgT4zV-GojekJInhW0epGcU1yWKWYVe3lyPksuvd_guKoqo6R8nZyxvM4LmuXnye-ZCSq92w7gAhivJkAzEdSkwhZZiZa2B7QEDSJAh1aGG4VuretHzYOyxn9GM4NuJtWBEZBecx-p2TA4y8UaSevQL3BKKrGnd8IHxzu1u3B90M01V71HK6_MI1rM0_vl1f1yPxvWEN1cj8fpuVYmyrTeop8x1MRNQNfa2g794I73EMB5pAxa8NY6HqyLHA_-TfJKcu3h8rBfJKvbm4f5Xbr4_vXbfLZIRYbrkMoC51lLCa-xJILlOS_LjmV53bKOFbTFRUdaSWjVSsBCAkAFomCCFLUsKLTsIvny7B3GtodOgAmO62Zwqudu21iumn9fjFo3j3ZqalbUZVZHwYeDwNmnEXxoeuUFaM0N2NE3tMSUVIxmNKLv_0M3dnTxW_cULrI69iJSH58p4az3DuQxDMHNrkDNSYEi_e40_5H9Wxf2B-jVxZA</recordid><startdate>20220808</startdate><enddate>20220808</enddate><creator>Shaharyar, Md Adil</creator><creator>Bhowmik, Rudranil</creator><creator>Afzal, Obaid</creator><creator>Altamimi, Abdulmalik S A</creator><creator>Alzarea, Sami I</creator><creator>Almalki, Waleed Hassan</creator><creator>Ali, Sk Zeeshan</creator><creator>Mandal, Pallab</creator><creator>Mandal, Avishek</creator><creator>Ayoob, Mohd</creator><creator>Kazmi, Imran</creator><creator>Karmakar, Sanmoy</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2319-340X</orcidid><orcidid>https://orcid.org/0000-0003-1881-5219</orcidid><orcidid>https://orcid.org/0000-0003-4007-4023</orcidid><orcidid>https://orcid.org/0000-0002-4188-5592</orcidid></search><sort><creationdate>20220808</creationdate><title>Anti-Hypertensive Activity of Some Selected Unani Formulations: An Evidence-Based Approach for Verification of Traditional Unani Claims Using LC-MS/MS for the Evaluation of Clinically Relevant Blood Parameters in Laboratory Rats</title><author>Shaharyar, Md Adil ; Bhowmik, Rudranil ; Afzal, Obaid ; Altamimi, Abdulmalik S A ; Alzarea, Sami I ; Almalki, Waleed Hassan ; Ali, Sk Zeeshan ; Mandal, Pallab ; Mandal, Avishek ; Ayoob, Mohd ; Kazmi, Imran ; Karmakar, Sanmoy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-f6054b21a90f1c355a77d3459b3d362b06d1bf128bfe0cfeee8ec63c169f62eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Animals</topic><topic>Antihypertensives</topic><topic>Blood pressure</topic><topic>Clinical medicine</topic><topic>Electrocardiography</topic><topic>Hypertension</topic><topic>Laboratories</topic><topic>Medical practices</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Potassium</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shaharyar, Md Adil</creatorcontrib><creatorcontrib>Bhowmik, Rudranil</creatorcontrib><creatorcontrib>Afzal, Obaid</creatorcontrib><creatorcontrib>Altamimi, Abdulmalik S A</creatorcontrib><creatorcontrib>Alzarea, Sami I</creatorcontrib><creatorcontrib>Almalki, Waleed Hassan</creatorcontrib><creatorcontrib>Ali, Sk Zeeshan</creatorcontrib><creatorcontrib>Mandal, Pallab</creatorcontrib><creatorcontrib>Mandal, Avishek</creatorcontrib><creatorcontrib>Ayoob, Mohd</creatorcontrib><creatorcontrib>Kazmi, Imran</creatorcontrib><creatorcontrib>Karmakar, Sanmoy</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shaharyar, Md Adil</au><au>Bhowmik, Rudranil</au><au>Afzal, Obaid</au><au>Altamimi, Abdulmalik S A</au><au>Alzarea, Sami I</au><au>Almalki, Waleed Hassan</au><au>Ali, Sk Zeeshan</au><au>Mandal, Pallab</au><au>Mandal, Avishek</au><au>Ayoob, Mohd</au><au>Kazmi, Imran</au><au>Karmakar, Sanmoy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-Hypertensive Activity of Some Selected Unani Formulations: An Evidence-Based Approach for Verification of Traditional Unani Claims Using LC-MS/MS for the Evaluation of Clinically Relevant Blood Parameters in Laboratory Rats</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2022-08-08</date><risdate>2022</risdate><volume>11</volume><issue>15</issue><spage>4628</spage><pages>4628-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>Background: Systemic arterial hypertension, which is associated with an increased risk of cardiovascular disease(CVD), is the most significant modifiable risk factor for mortality and morbidity worldwide. WHO has recognized Unanipathy as an alternate system of medicine. The aim of the present study is to investigate the anti-hypertensive activity of some selected unani formulations using L-NAME model. Method: Group I or hypertensive control group: L-NAME administered for 7 days and left for the next 7 days; Group II or KASgroup: L-NAME administered (i.p) for 7 days and L-NAME + KAS (1000 mg/kg b.w) for the next 7 days; Group III or DMM group: L-NAME administered (i.p) for 7 days and L-NAME + DMM (2000 mg/kg b.w) for the next 7 days; Group IV or MSR group: L-NAME administered (i.p) for 7 days and L-NAME + MSR (300 mg/kg b.w) for the next 7 days; Group V or HJ group: L-NAME administered (i.p) for 7 days and L-NAME + HJ (113 mg/kg b.w) for the next 7 days; Group VI or KGS group: L-NAME administered (i.p) for 7 days and L-NAME +KGS (2000 mg/kg b.w) for the next 7 days. Non-invasive systolic blood pressure and RR-interval (ECG) was measured. Plasma was investigated forsodium, potassium, nitrite, ANP, adrenaline, noradrenaline and aldosterone on day 0, 7 and 14 using LC-MS/MS. Result: Treatment showed a non-significant lowreduction in SBP (systolic blood pressure) of KAS, MSR and HJ while that of DMM was quite significant (p &lt; 0.05), but in the case of KGS, SBP increased. DMM on day 14 significantly (p &lt; 0.05) reduced plasma nitrite while no significant plasma Na+ was noted. In the case of both DMM and KGS, potassium increased significantly (p &lt; 0.05) on day 14. No significant changes in plasma ANP and aldosterone was observed against DMM and KGS while blood levels of adrenaline and noradrenaline significantly (p &lt; 0.05) changed. No significant change in body weight was found. Conclusions: L-NAME KAS, MSR and HJ showed no change in SBP while DMM showed a significant reduction in SBP with decreased plasma nitrite. Probably, DMM may have anti-hypertensive activity mediated through NO inhibition while KGS may involve central sympathomimetic action.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35956245</pmid><doi>10.3390/jcm11154628</doi><orcidid>https://orcid.org/0000-0003-2319-340X</orcidid><orcidid>https://orcid.org/0000-0003-1881-5219</orcidid><orcidid>https://orcid.org/0000-0003-4007-4023</orcidid><orcidid>https://orcid.org/0000-0002-4188-5592</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2077-0383
ispartof Journal of clinical medicine, 2022-08, Vol.11 (15), p.4628
issn 2077-0383
2077-0383
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9369749
source PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Animals
Antihypertensives
Blood pressure
Clinical medicine
Electrocardiography
Hypertension
Laboratories
Medical practices
Medical research
Medicine
Potassium
title Anti-Hypertensive Activity of Some Selected Unani Formulations: An Evidence-Based Approach for Verification of Traditional Unani Claims Using LC-MS/MS for the Evaluation of Clinically Relevant Blood Parameters in Laboratory Rats
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T04%3A24%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-Hypertensive%20Activity%20of%20Some%20Selected%20Unani%20Formulations:%20An%20Evidence-Based%20Approach%20for%20Verification%20of%20Traditional%20Unani%20Claims%20Using%20LC-MS/MS%20for%20the%20Evaluation%20of%20Clinically%20Relevant%20Blood%20Parameters%20in%20Laboratory%20Rats&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Shaharyar,%20Md%20Adil&rft.date=2022-08-08&rft.volume=11&rft.issue=15&rft.spage=4628&rft.pages=4628-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm11154628&rft_dat=%3Cproquest_pubme%3E2700649111%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2700649111&rft_id=info:pmid/35956245&rfr_iscdi=true